| Autor: |
H. Kirchner, J. Atzpodien, Deicher H, S. Quesada, R. Leo, P. A. Palmer, C. R. Franks, D. Peest, S. Stannat-Kießling, R. Hein, P. Evers, A. G. Schmidt |
| Rok vydání: |
1992 |
| Předmět: |
|
| Zdroj: |
Cytokines in Hemopoiesis, Oncology, and AIDS II ISBN: 9783540552420 |
| Popis: |
The median survival of patients with stage II or III multiple myeloma (MM) treated with chemotherapy is 3 years. Since the introduction of melphalan/prednisone treatment no significant improvement in this prognosis has been attained even by applying other chemotherapy combinations [1]. Therefore, alternative therapy modalities should be developed and tested. Monoclonal immunoglobulin (mIg) produced by the malignant plasma cells is a marker for MM and in vivo an indicator for tumor cell mass changes during therapy [2, 3]. Measuring mIg in supernatants of short-term cultures from myeloma bone marrow cells is a system which can be used for in vitro studies on the regulation of individual myeloma clones [4]. Previous experiments provided strong evidence for growth control of myeloma tumor cells by autologous CD3 + lymphocytes. The suppressive effect of these autologous T lymphocytes can be enhanced by stimulation with anti-CD3 antibodies or interleukin 2 (IL-2) [5]. Trials in patients with other malignant diseases such as renal cell carcinoma, colorectal carcinoma, melanoma or non-Hodgkin’s lymphoma using recombinant IL-2 (rIL-2) for in vivo activation of cytotoxic T lymphocytes and natural killer (NK) cells or for ex vivo generation of lymphokine-activated killer cells clearly showed enhancement of immunological effector cells and significant though limited antitumor effects [6–8]. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
